Disc Medicine, Inc. — Director's Dealing 2021

Feb 10, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemini Therapeutics, Inc. /DE (GMTX)
CIK: 0001816736
Period of Report: 2021-02-05

Reporting Person: Meyenburg Jason Patrick (Director, President & CEO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.1563	2029-11-11	Common Stock (586368)		Direct
Stock Option (Right to Buy)	$2.5234	2030-03-10	Common Stock (129840)		Direct
Stock Option (Right to Buy)	$7.6160	2030-10-15	Common Stock (256768)		Direct

Footnotes

F1: Stock option to purchase common stock issued as merger consideration pursuant to the Agreement and Plan of Merger by and among Gemini Therapeutics Inc., FS Development Corp., FSG Merger Sub Inc. and Shareholder Representative Services LLC, dated as of October 15, 2020 (the "Merger Agreement"). This option shall vest and become exercisable 25% of the shares vesting on the one-year anniversary of the Vesting Start Date, September 23, 2019, and the remainder vesting ratably on a monthly basis over the following 36 months, subject to continued employment.

F2: Stock option to purchase common stock issued as merger consideration pursuant to the Merger Agreement. This option shall vest and become exercisable over a period of four years from the Vesting Start Date, March 11, 2020, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

F3: Stock option to purchase common stock issued as merger consideration pursuant to the Merger Agreement. This option shall vest and become exercisable 25% shall vest on the one year anniversary of the Vesting Start Date, and the remainder shall vest over a period of 36 months thereafter, provided that as of each such vesting date the Grantee remains in a business relationship with the Company.